research use only
Cat.No.S1988
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Other Peroxidases Inhibitors | ML-210 4-Aminobenzohydrazide Verdiperstat PF-06282999 JKE-1674 ZX703 FINO2 Alkyne tyramide MPO-IN-28 4-Methylesculetin |
|
In vitro |
DMSO
: 80 mg/mL
(469.95 mM)
Ethanol : 19 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 170.23 | Formula | C7H10N2OS |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 51-52-5 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | NSC 6498, NSC 70461 | Smiles | CCCC1=CC(=O)NC(=S)N1 | ||
| Targets/IC50/Ki |
thyroperoxidase
5'-deiodinase
|
|---|---|
| In vivo |
Propylthiouracil-induced hypothyroidism reduces oxidative damage in the lung, hepatic, renal and ileal tissues probably due to hypometabolism in rats, which is associated with decreased production of reactive oxygen metabolites and enhancement of antioxidant mechanisms. This compound-induced congenital hypothyroidism upregulates vimentin phosphorylation and depletes antioxidant defenses in immature rat testis. It results in lesser concentrations of thyroxine (T4) and triiodothyronine (T3), greater concentrations of follicle stimulating hormone (FSH) and luteinizing hormone (LH) peptides, and increase in steroidogenic gene expression after 12 hours and 48 hours in zebrafish. This compound-induced hypothyroidism is associated with increased tolerance of the isolated rat heart toischaemia-reperfusion. It dramatically reduces thyroid hormones on PND21 and produced deficits in body weight that persisted to adulthood in developing rats. This compound inhibits both the synthesis of thyroid hormones in the thyroid gland and the conversion of T4 to its active form, T3. This treatment significantly increases circulating TSH at both P3 and P7. This exposure of adult rats, at a dose inducing modest reductions in circulating T4 concentrations and no significant effect on brain BDNF, significantly alteres the thyroid hormones and hippocampal BDNF levels in the offspring at 3 and 7 d after birth.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT02390180 | Completed | Taste Qualities|Primary Tastes |
Purdue University |
October 2014 | -- |
| NCT01097915 | Completed | Dysgeusia |
University of Cagliari |
October 2009 | -- |
| NCT00570466 | Completed | Type 2 Diabetes |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Baylor College of Medicine |
January 2008 | Not Applicable |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.